Several gene mutations, deletions or chromosomal rearrangements are involved in the onset of neuroblastoma and are associated with poor outcome, such as ALK, PHOX2B and MYCN gene amplification [4, 5]. This evidence concerns the gene MYCN and neuroblastoma.